Lung Cancer Clinical Trial

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Summary

The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years
Histologically or cytologically confirmed SCLC
Extensive-stage, unable to be encompassed in a tolerable radiation plan
Progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy
Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1
Minimum life expectancy of 12 weeks

Exclusion Criteria:

Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology
Untreated or symptomatic central nervous system (CNS) metastases
Active hepatitis B or hepatitis C virus infection
Eligible for participation in any Amgen-sponsored ongoing clinical study of the investigational product
Currently or previously enrolled in a prior tarlatamab study
Female participants and/or male participants with female partners who are pregnant, breastfeeding, planning to become pregnant or donate eggs while on study through 72 days after the last dose of tarlatamab
Male and female participants unwilling to practice abstinence and/or use protocol specified method of contraception

Study is for people with:

Lung Cancer

Study ID:

NCT06064500

Recruitment Status:

Available

Sponsor:

Amgen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Yale School of Medicine
New Haven Connecticut, 06520, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach Florida, 33140, United States
Martin Memorial Health System
Stuart Florida, 34994, United States
Nebraska Cancer Specialists
Omaha Nebraska, 68106, United States
Perlmutter Cancer Center at New York University Langone Hospital - 34th Street
New York New York, 10016, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
University of Virginia
Charlottesville Virginia, 22903, United States
Cancer Care Northwest - South
Spokane Washington, 99202, United States
Associacao Hospitalar Moinhos de Vento
Porto Alegre Rio Grande Do Sul, 90035, Brazil
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
Sao Paulo São Paulo, 01308, Brazil
Okayama University Hospital
Okayama-shi Okayama, 700-8, Japan

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Study ID:

NCT06064500

Recruitment Status:

Available

Sponsor:


Amgen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.